New Insight Into Mechanisms of Hepatic Encephalopathy: An Integrative Analysis Approach to Identify Molecular Markers and Therapeutic Targets

Gray matter alterations and neurotransmitter system associations in hepatitis B virus-related cirrhosis: insights into neuropathogenesis and therapeutic targets

INTRODUCTION

The associations between gray matter (GM) change and neurotransmitter systems in hepatitis B virus-related cirrhosis (HBV-RC) are still poorly understood.

METHODS

We recruited 60 HBV-RC patients and 60 healthy controls (HCs). Difference of GM volume between HBV-RC and HC groups was evaluated at global and voxel levels. The potential relationship between GM morphology and prognostic models of liver function was evaluated at voxel level in HBV-RC patients. The spatial correspondence between regional GM alteration and the distribution of multiple neurotransmitter systems in HBV-RC compared to healthy controls was assessed by the JuSpace toolbox covering various neurotransmitter maps.

RESULTS

Total GM volume in HBV-RC group was smaller than in HC group (p < 0.05), and the pattern of GM volume alterations showed significantly increased volume in bilateral thalamus and ventral diencephalon and decreased volume in bilateral basal ganglia and cerebellum (p < 0.05, FWE corrected). In HBV-RC group, the volume of left superior frontal gyrus medial segment and right middle frontal gyrus was positively correlated with serum albumin level and negatively correlated with ALBI score, and serum bilirubin level was negatively correlated with right hippocampus and caudate (p < 0.05, FWE corrected). GM alterations in HBV-RC patients relative to HCs were significantly associated with the intrinsic distribution of various neurotransmitter pathways, including GABAergic, cholinergic, serotonergic, and dopaminergic (p < 0.05).

CONCLUSION

The pattern of GM alteration correlated with liver function and specific neurotransmitter deficits in HBV-RC patients. These findings provide new insight into the complex neuropathogenesis of HBV-RC and the possible therapeutic targets based on neurotransmitter modulation.

The landscape of the methodology in drug repurposing using human genomic data: a systematic review

The process of drug development is expensive and time-consuming. In contrast, drug repurposing can be introduced to clinical practice more quickly and at a reduced cost. Over the last decade, there has been a significant expansion of large biobanks that link genomic data to electronic health record data, public availability of various databases containing biological and clinical information and rapid development of novel methodologies and algorithms in integrating different sources of data. This review aims to provide a thorough summary of different strategies that utilize genomic data to seek drug-repositioning opportunities. We searched MEDLINE and EMBASE databases to identify eligible studies up until 1 May 2023, with a total of 102 studies finally included after two-step parallel screening. We summarized commonly used strategies for drug repurposing, including Mendelian randomization, multi-omic-based and network-based studies and illustrated each strategy with examples, as well as the data sources implemented. By leveraging existing knowledge and infrastructure to expedite the drug discovery process and reduce costs, drug repurposing potentially identifies new therapeutic uses for approved drugs in a more efficient and targeted manner. However, technical challenges when integrating different types of data and biased or incomplete understanding of drug interactions are important hindrances that cannot be disregarded in the pursuit of identifying novel therapeutic applications. This review offers an overview of drug repurposing methodologies, providing valuable insights and guiding future directions for advancing drug repurposing studies.